WD-01 CAR-T
CRC (Colorectal Cancer)
Wondercel Biotech (ShenZhen)Early Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 81/ 100
Competitive context
839 Active assets in the CRC (Colorectal Cancer) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
MARBLE DUST James Varani | Phase 2/3 | BB |
FLUOROURACILUM Washington University School of Medicine | Phase 4 | BB |
PANITUMUMAB M.D. Anderson Cancer Center | Phase 3 | BB |
Cetuximab Shanghai Henlius Biotech | Phase 4 | BB |
View all 50 →
Same molecule, other indications
WD-01 CAR-T is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →